Capivasertib is an AKT inhibitor that demonstrated activity in AKT1-mutant hormone-receptor-positive aBC, not only in combination with fulvestrant but also in terms of a monotherapy [57]. This evidence concerns the gene NR4A1 and aneurysmal bone cyst.